Miracle Surrogacy attends ESHRE 2026 in London

Miracle Surrogacy joined the 42nd Annual Meeting of the European Society of Human Reproduction and Embryology in London from July 5 to 8, 2026, to track new work in IVF, embryology, genetics and artificial intelligence. The agency said the conference helps it stay aligned with evidence-based fertility care and strengthen ties with clinics and specialists serving intended parents.

Why it matters: - ESHRE is one of the biggest scientific meetings in reproductive medicine, so the conference can shape how fertility care develops worldwide. - For intended parents pursuing international family building, advances in embryo selection, genetics and laboratory quality can affect treatment decisions, safety and outcomes. - Miracle Surrogacy said staying connected to the scientific community helps the agency bring evidence-based developments into its work with intended parents.

What happened: - Miracle Surrogacy participated in the 42nd Annual Meeting of the European Society of Human Reproduction and Embryology in London from July 5 to 8, 2026. - The conference gathered physicians, embryologists, geneticists, researchers, fertility specialists and industry leaders. - Miracle Surrogacy was represented by Chief Operating Officer Mario Lara, Business Development Manager Sammir Braham and Manager of Clinical Services Karla Moncada. - The team met with fertility professionals and industry partners while following scientific sessions.

The details: - The scientific program focused on artificial intelligence in embryology, embryo selection, preimplantation genetic testing (PGT), IVF laboratory practices, reproductive genetics, safety and quality standards in assisted reproductive technology (ART), ethical and legal issues, and patient-centered fertility care. - Sessions also covered fertility preservation, reproductive endocrinology, embryo development and the integration of advanced technologies into clinical practice. - Miracle Surrogacy said the meeting also offered a chance to strengthen relationships with European fertility professionals and organizations serving intended parents. - The company said collaboration among fertility clinics, laboratories, legal professionals and patient support groups is increasingly important as international reproductive care expands. - Mario Lara said conferences like ESHRE help the company stay connected with the scientific community and maintain relationships with clinics, laboratories and reproductive medicine professionals around the world. - Karla Moncada said direct access to research presentations helps the company evaluate new scientific evidence from the experts conducting the work.

Between the lines: - The conference reinforced a broader shift in fertility care toward more personalized, data-driven and evidence-based treatment. - Advances in artificial intelligence, genetics and embryo assessment are only useful if they are backed by rigorous evidence and ethical oversight. - For a cross-border surrogacy provider, staying close to European and global research can be a competitive and clinical advantage, especially when intended parents are making high-stakes treatment decisions.

What's next: - Miracle Surrogacy said it will continue engaging with the global fertility community and applying evidence-based practices. - The company plans to keep monitoring developments in IVF, embryology, reproductive genetics and artificial intelligence as they move toward clinical use. - Ongoing collaboration across clinics, labs and support organizations is likely to remain central as international fertility care evolves.

The bottom line: - Miracle Surrogacy used ESHRE 2026 to signal that its approach to international family building is tied to current research, clinical collaboration and emerging fertility technology.